_256_384.jpg)
News | December 08, 2021
IPM registers 6 % yoy revenue growth in Nov 2021.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
The company is moving towards complex and more differentiated products
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Nelarabine is in a class of medications called antimetabolites
Subscribe To Our Newsletter & Stay Updated
